Dasatinib combined with interferon-alfa induces a complete cytogenetic response and major molecular response in a patient with chronic myelogenous leukemia harboring the T315I BCR-ABL1 mutation

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue SUPPL.1, 2011, Pages

  Cornelison, A Megan ^a   Welch, Mary Alma ^a   Koller, Charles ^a   Jabbour, Elias ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Chronic myelogenous leukemia (CML); Combination; Kinase domain mutations; T315I mutation; TKI resistance

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; DASATINIB; IMATINIB; KW 2449; PROTEIN BCR ABL1; UNCLASSIFIED DRUG;

ADULT; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONFERENCE PAPER; CYTOGENETICS; DEATH; DIABETES MELLITUS; DISEASE CONTROL; DRUG DOSE INCREASE; DRUG RESPONSE; DRUG WITHDRAWAL; ESCHERICHIA COLI; HUMAN; MALE; MOLECULAR BIOLOGY; MUTATION; PLEURA EFFUSION; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT FAILURE;

EID: 84860563776     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2011.03.032     Document Type: Conference Paper

References (19)

1. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with ima-tinib mesylate. Leukemia 2006; 20:1767-73.
2. Apperley JF. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol 2007; 8:1018-29.
3. Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009; 16:1222-31.
4. Jabbour E, Kantarjian H, Jones D, et al. Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy. Blood 2008; 112:53-5.
5. Weisberg E, Manley PQ, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-abl. Cancer Cell 2005; 7:129-41.
6. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006; 354:2531-41.
7. Kantarjian HM, O'Brien S, Smith TL, et al. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine. J Clin Oncol 1999; 17:284-92.
8. Kantarjian HM, O'Brien S, Cortes JE, et al. Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis. Cancer 2003; 97:1033-41.
9. Cortes JE, Khoury HJ, Corm S, et al. Multicenter open label study of subcutaneous (SC) omacetaxine (OMA) in imatinib (IM)-resistant chronic myeloid leukemia (CML) in patients (Pts) with the T315I mutation [abstract]. J Clin Oncol 2008; 26:7021.
10. O'Brien S, Giles F, Talpaz M, et al. Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelog-enous leukemia in early chronic phase. Cancer 2003; 98:888-93.
11. Cortes J, Roboz GJ, Kantarjian H, et al. A phase I dose escalation study of KW-2449, an oral multikinase inhibitor against FLT3, Abl, FGFR1, and Aurora in patients with relapsed/refractory AML, treatment resistant/intolerant CML, ALL, and MDS [abstract]. Blood 2007; 110:909.
12. Gontarewicz A, Balabanov S, Keller G, et al. Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I. Blood 2008; 111:4355-64.
13. Paquette RL, Shah NP, Sawyers CL, et al. PHA-739538, an aurora kinase inhibitor, induces clinical responses in chronic myeloid leukemia harboring T315I mutations of BCR-ABL [abstract]. Blood 2007: 110:907.
14. Cortes J, Talpaz M, Deininger M, et al. A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations [abstract]. Blood 2009; 114:643.
15. Van Etten RA, Chan WW, Zaleskas VM, et al. Switch pocket inhibitors of the ABL tyrosine kinase: distinct kinome inhibition profiles and in vivo efficacy in mouse models of CML and B-lymphoblastic leukemia induced by BCR-ABL T315I [abstract]. Blood 2008; 112:576.
16. Guilhot F, Preudhomme C, Guilhot J, et al. Significantly higher rates of undetect-able molecular residual disease and molecular responses with pegylated form of interferon a2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the Spirit Phase III randomized trial of the French CML Group (FI LMC) [abstract]. Blood 2009; 114; 340.
17. Burchert A, Muller MC, Kostrewa P, et al. Interferon alpha 2a (IFN) maintenance therapy after imatinib plus IFN induction therapy in chronic myeloid leukemia (CML) induces stable long-term molecular remissions and is associated with increased proteinase 3 (PR3) expression and the presence of PR1-specific T-cells [abstract]. Blood 2009; 114:647.
18. Peudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med 2010; 363:2511-21.
19. Al-Ameri A, Kantarjian H, Borthakur G, et al. Opportunistic infections are uncommon with dasatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP) [abstract]. Blood 2009; 114: 1120.